Stents are classified as implants under both U.S. and international regulatory frameworks. The U.S. Food and Drug Administration categorizes coronary stents as Class III medical devices, the highest-risk category, which also includes pacemakers and heart valves. But the relationship between “stent” and “implant” is more nuanced than a simple yes-or-no, because stents vary enormously in how long they stay in the body, what they are made of, and where they are placed.
How the FDA Classifies Stents
The FDA sorts medical devices into three risk classes. Class I covers low-risk items like bandages and tongue depressors. Class II includes moderately complex devices such as powered wheelchairs. Class III is reserved for devices that pose the greatest potential risk and require the most rigorous premarket approval. Stents land squarely in Class III alongside implantable pacemakers, heart valves, and certain diagnostic tests.1JAMA Internal Medicine. Medical Device Recalls and the FDA Approval Process That Class III designation reflects the fact that stents are placed inside the body, interact directly with tissue and blood, and carry meaningful risks if they malfunction.
The classification matters for more than just bureaucratic reasons. A Class III designation means manufacturers must submit a premarket approval application with clinical trial data proving the device is safe and effective, rather than simply showing it is similar to something already on the market. For patients, this means that any stent approved through the standard pathway has been tested more rigorously than devices in the lower categories. Post-market surveillance studies continue to track outcomes after approval, monitoring real-world performance in broad populations.2PubMed. The TRANSEVER registry – A prospective, open-label, multicentre, post market surveillance study of ISAR SUMMIT polymer-free Everolimus eluting stent in a real-world Indian population of patients with coronary artery disease
Why “Implant” Gets Complicated With Stents
When most people hear “implant,” they picture something permanent: a hip joint, a pacemaker, dental hardware. Many stents do fit that image. A bare metal coronary stent, once expanded inside an artery, stays there for the rest of your life. The artery’s inner lining gradually grows over it, incorporating it into the vessel wall. In that sense, it is as permanent as any orthopedic implant.
But not all stents are meant to stay. Ureteral stents, the soft tubes placed in the urinary tract to keep urine flowing past a blockage, are typically removed after days or weeks. Esophageal stents used to open a narrowed swallowing passage may also be temporary, particularly self-expandable designs placed for benign conditions.3PubMed Central. A comprehensive review of esophageal stents These devices are still classified as implants during the time they are inside the body, but their intended lifespan is measured in weeks rather than decades.
Then there is a third category that blurs the line further: biodegradable stents. These are made from materials designed to dissolve after they have done their job. The idea is that a coronary stent only needs to hold an artery open during the critical healing window. Once the vessel has remodeled and stabilized, having a permanent metal scaffold inside it offers no further benefit and may even cause problems. Biodegradable stents aim to provide temporary scaffolding and then progressively disappear.4PubMed. Developments in metallic biodegradable stents They are implants that are engineered not to remain implants.
Drug-Eluting Stents and the Combination Product Problem
A bare metal stent is a straightforward device: a metal tube that holds open a vessel. But most coronary stents placed today are drug-eluting stents, which are coated with medication that slowly releases into the surrounding tissue to prevent the artery from re-narrowing. This creates a regulatory headache, because the product is simultaneously a device and a drug delivery system. The FDA’s regulatory pathway for these combination products is less clear-cut than for devices or drugs considered alone.5PubMed Central. Combination Products And the FDA: Issues and Answers
The distinction matters practically. Drug-eluting stents require patients to take dual antiplatelet therapy, typically aspirin plus a second blood-thinning medication, for at least twelve months after placement. A joint advisory from the American Heart Association, the American College of Cardiology, and several other professional societies stresses the importance of this regimen and warns against stopping it prematurely.6PubMed. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents The drug coating suppresses tissue growth around the stent, which prevents re-narrowing but also means the stent takes longer to become fully integrated into the artery wall. Stopping antiplatelet medication too early raises the risk of a blood clot forming on the stent’s exposed surface.
Research on sirolimus-eluting stents found that patients who stopped both antiplatelet medications had significantly higher rates of stent clotting compared to those who stayed on therapy, and this elevated risk persisted well beyond the first year.7PubMed. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation The combination-product nature of drug-eluting stents means they carry obligations that a purely mechanical implant would not.
How the Body Responds to a Stent
When a stent is placed inside an artery, the body treats it much the way it would treat any wound. Deploying the stent crushes and strips away part of the vessel’s inner lining and stretches the arterial wall. What follows is a healing cascade: platelets rush to the injured site and form a thin clot, an inflammatory response moves in, and then cells begin to multiply and migrate to cover the foreign object. Over time, new tissue grows over the metal struts, and the vessel remodels around the stent.8Cardiovascular Research. Biological responses in stented arteries
This process is essentially wound healing, and like all wound healing, it can go wrong. Too much tissue growth leads to restenosis, where the artery narrows again inside the stent. Too little healing leaves the stent’s metal surface exposed to flowing blood, which is the setup for clot formation. Drug-eluting stents were developed specifically to tamp down the excessive tissue growth that plagued earlier bare metal designs, but they shift the balance toward slower healing, which is why the prolonged antiplatelet therapy is necessary.
Stents Beyond the Heart
Coronary stents get the most attention, but stents are used throughout the body, and their classification as implants applies across all of these settings. Esophageal stents help patients who have trouble swallowing, often because of tumors that narrow the food pipe. Self-expandable esophageal stents have become a primary palliative tool for inoperable esophageal cancers, and newer designs are also used for benign strictures.3PubMed Central. A comprehensive review of esophageal stents
Ureteral stents, placed in the tubes connecting the kidneys to the bladder, are among the most commonly used stents and illustrate how context changes performance. In patients whose ureter is blocked by something inside the tube itself, ureteral stents work reliably. But when the blockage comes from outside pressure, such as a tumor pressing on the ureter, failure rates climb sharply. At two major hospitals, stents placed for external obstruction failed roughly 40 to 45 percent of the time, compared to zero failures for internal blockages.9PubMed Central. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions For patients with malignant ureteral obstruction, permanent metallic mesh stents have been tried as a longer-lasting alternative to the soft plastic stents that need frequent replacement. In one study, about a quarter of these metallic ureteral stents required additional procedures, but they still reduced the total number of interventions patients needed compared to repeated temporary stenting.10Elsevier / Urology. Early Application of Permanent Metallic Mesh Stent in Substitution for Temporary Polymeric Ureteral Stent Reduces Unnecessary Ureteral Procedures in Patients With Malignant Ureteral Obstruction
Biliary stents keep bile ducts open. Tracheal and bronchial stents maintain airway patency. Stents are placed in peripheral arteries in the legs, in the carotid arteries feeding the brain, and in the veins. Each location brings its own mechanical demands, biological responses, and risk profiles, but the shared feature is that a foreign structure is placed inside the body to hold open a passage. That is implantation, regardless of whether it is meant to last a week or a lifetime.
Can You Get an MRI With a Stent?
This is one of the most common concerns patients have after receiving a stent, and the answer is reassuring. A comprehensive review of all major stents available worldwide found that current cardiovascular stents are MRI safe and that MRI can be performed at any time after placement.11PubMed. Are Current Cardiovascular Stents MRI Safe? Testing of coronary stents in 1.5-Tesla MRI machines showed no meaningful heating and no motion of the stents during scanning.12PubMed. Coronary arterial stents: safety and artifacts during MR imaging
The stent will produce some artifact on the MRI image, meaning the area right around the stent may appear distorted, which can make it harder to evaluate that specific section of the artery. But the scan itself is not dangerous. This was a genuine concern in the early days of stenting, when some devices contained materials with stronger magnetic properties, but modern stents are made from alloys specifically chosen to minimize interaction with MRI fields. If you have a stent and need an MRI for an unrelated reason, the stent should not be a barrier.
Living With a Stent
The psychological dimension of having a stent is underappreciated. Qualitative research on patients living with coronary stents consistently finds that anxiety is a central experience, particularly worry about the future and uncertainty about what the stent means for long-term health.13PubMed. Patient experiences of living with coronary stent A separate study of patients who received emergency stenting found the same themes: anxiety about the procedure itself and anxiety about what life would look like afterward, alongside a felt need for lifestyle changes.14PubMed. Emergency percutaneous coronary intervention and stent implantation: Patients’ lived experiences
Part of this anxiety may stem from uncertainty about what category the device falls into. Patients told they have “an implant” sometimes worry they now have a permanent foreign object that will complicate every future medical decision. Understanding that a stent is integrated into the vessel wall, that it is MRI compatible, and that the body’s own tissue grows around it can help reduce some of that worry. The medication burden, particularly with drug-eluting stents, adds its own stress: remembering to take daily antiplatelet drugs, worrying about what happens if you miss a dose, and navigating situations like dental procedures or surgeries where the medication may need to be managed carefully.
Tracking what happens to patients after stent placement is itself a challenge. A demonstration project looking at how device identifiers could be transmitted from hospitals to insurers found that among patients receiving drug-eluting stents, about 9 percent were rehospitalized at the same facility, but an additional 12 percent were rehospitalized elsewhere. For emergency department visits, the numbers were 15 percent at the original facility and another 10 percent at other hospitals.15Lippincott Williams & Wilkins (LWW) / Journal of Patient Safety. Transmitting Device Identifiers of Implants From the Point of Care to Insurers: A Demonstration Project Because patients often seek care at different facilities, the full picture of post-stent outcomes can be difficult to assemble without systems that track the specific device implanted.
Stents in Children
Stenting is primarily associated with older adults treating atherosclerotic disease, but stents are also used in children with congenital heart defects, and this is where the implant classification creates real practical dilemmas. A child’s blood vessels are still growing. A stent that fits perfectly in an infant’s pulmonary artery will be too small by the time that child is a teenager. No vascular stents are widely approved or accessible for implantation in infants and young children.16Journal of the American Heart Association. OPTILOW: A Low-Profile Approach for Implanting Optimus-L Stents in Infants and Children
The peripheral stents typically used in pediatric cases max out at around 10 to 12 millimeters, which is not enough to reach adult-sized dimensions in the pulmonary arteries or aorta. Children who receive stents will eventually need the stent either fractured with ultra-high-pressure balloons so a larger one can be placed, or surgically removed. Both approaches carry risks, and neither is ideal. This situation highlights a gap between the implant’s design life and the patient’s biological timeline, a problem that does not arise in the same way for adults whose vessels are done growing.
When a Stent Needs to Come Out
Most coronary stents are never removed. Once tissue has grown over the metal struts, extracting the stent would mean tearing out part of the artery wall. But rare complications can force the issue. Stent infection, though extremely uncommon, has been documented in the medical literature, and it almost always requires surgical removal of the infected stent along with the surrounding artery segment. Even with aggressive treatment, outcomes in reported cases have been poor, with the majority of patients dying.17PubMed Central. Coronary artery stent infection The rarity and severity of stent infection underscores why sterile technique during placement and post-procedure monitoring are taken so seriously.
For non-vascular stents that are designed to be removed, retrieval is usually straightforward. Ureteral stents have a small string or can be grasped with a scope. Esophageal stents are removed endoscopically. The difficulty of removal scales with how much tissue has grown into or around the device, which is another reason temporary stents are typically retrieved on schedule rather than left in longer than planned.
Legal and Liability Dimensions of Stents as Implants
Classifying a device as an implant carries legal weight. The history of implantable medical devices includes high-profile liability cases that shaped the industry. Suppliers of implantable materials pulled back from the market after Dow Corning was forced into bankruptcy over silicone breast implant claims, a process that lasted nine years and ended with a $3.2 billion settlement. The Biomaterials Access Assurance Act, passed in 1998, now provides legal protections for raw material suppliers that were not available during that era.18ACS Publications. MEDICAL POLYMERS RENAISSANCE: Despite POTENTIAL LIABILITIES, new suppliers of medical device polymers enter the market
For stent patients, the implant designation means the device falls under product liability frameworks that cover implanted devices. If a stent is defective and causes harm, the legal pathway for patients is shaped by the fact that it was classified as a high-risk implant requiring premarket approval. The regulatory and legal infrastructure around implants is designed with the understanding that these devices are inside people and that failure can be catastrophic. That infrastructure, built partly in response to past disasters, is the reason stent manufacturers face the level of scrutiny they do.
Smart Stents and Embedded Sensors
Researchers are working on stents that go beyond passive scaffolding. So-called smart stents incorporate embedded sensors that can detect problems like restenosis or incomplete healing of the vessel lining from inside the body. These systems are still largely in the research phase, but they represent an interesting evolution of what an implant can be: not just a structural support, but a monitoring device that provides ongoing diagnostic information.19Wiley Online Library (Medical Devices & Sensors / CrossRef). Perspectives on smart stents with sensors: From conventional permanent to novel bioabsorbable smart stent technologies
If smart stents reach clinical use, they would further blur classification boundaries. A stent that monitors blood flow and wirelessly transmits data to a physician’s office is simultaneously an implant, a diagnostic device, and potentially (if it adjusts drug delivery) a combination product. Regulatory frameworks built around the traditional categories of device, drug, and diagnostic will need to accommodate objects that are all three at once. For patients, the appeal is obvious: a stent that can alert your doctor to a developing problem before you feel any symptoms could catch complications early enough to treat them with medication rather than another procedure.